

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): April 14, 2020

**Fluidigm Corporation**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**001-34180**  
(Commission File Number)

**77-0513190**  
(I.R.S. Employer Identification Number)

**2 Tower Place, Suite 2000, South San Francisco, California 94080**  
(Address of Principal Executive Offices) (Zip Code)

**(650) 266-6000**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common stock, par value \$0.001 per share</b>	<b>FLDM</b>	<b>Nasdaq Global Select Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On April 14, 2020, Fluidigm Corporation issued a press release announcing preliminary financial results for the quarter ended March 31, 2020. The Company also announced the withdrawal of its full year 2020 guidance in light of the uncertainty surrounding the ongoing and evolving novel coronavirus pandemic. A copy of the press release is furnished herewith as Exhibit 99.1.

The foregoing information in this Current Report on Form 8-K, including exhibit 99.1 attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such future filing.

**Item 9.01. Financial Statements and Exhibits.****(d) Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Fluidigm Corporation Press Release dated April 14, 2020.</a>

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Fluidigm Corporation**

Date: April 14, 2020

By: /s/ Vikram Jog  
Vikram Jog  
Chief Financial Officer

## Fluidigm Provides Update on COVID-19 Impact and Preliminary Revenue Estimate for First Quarter 2020

SOUTH SAN FRANCISCO, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today provided an update on the impact of the COVID-19 pandemic on its business and announced preliminary revenue estimates for the quarter ended March 31, 2020.

Fluidigm has been actively responding to the pandemic by protecting our employees and serving urgent customer needs while managing our liquidity.

### Protecting our Employees

As Fluidigm is a designated essential business, our employees have been working from home offices or our laboratories and offices, and in some cases, at customer sites. We have implemented health and safety practices in accordance with evolving government and public health agency guidelines in all of our facilities around the world.

### Serving our Customers

Fluidigm has been working with a growing body of researchers around the world who are aggressively responding to the pandemic. We believe our microfluidics and mass cytometry capabilities can play a significant role in virus detection as well as immune profiling of the impacted population. Furthermore, we believe our solutions will be important to the durable response from government and medical institutions.

Examples of recent activity include:

- A global mix of customers utilizing or evaluating our microfluidic platforms for ultrahigh-throughput RNA-based virus detection tests.
- Clinical researchers deploying Fluidigm CyTOF<sup>®</sup> technology and/or our Maxpar<sup>®</sup> Direct<sup>™</sup> Immune Profiling Assay<sup>™</sup> to characterize the immune response to the virus or evaluate immune response related to potential therapies and vaccine candidates. A recent example was the publication of a clinical study<sup>1</sup> to evaluate stem cell therapy as a potential treatment for COVID-19 pneumonia in China.
- Novel approaches to COVID-19 related opportunities, including a recent announcement that a consortium of medical schools funded by the U.S. Defense Department's Defense Advanced Research Projects Agency (DARPA) is developing a new epigenetic test employing our unique microfluidics technology for early COVID-19 detection.

### Managing our Liquidity

We are actively managing our operating expenses and cash flows in response to the evolving market conditions.

Additional details regarding Fluidigm's activities related to the COVID-19 pandemic can be found at [fluidigm.com](http://fluidigm.com) and [investors.fluidigm.com](http://investors.fluidigm.com)

### First Quarter Preliminary Financial Highlights

Total revenue is expected to be approximately \$27.6 million, including approximately \$3 million of license revenue. We observed a significant slowdown in customer activity beginning in China, spreading to all regions of the world as the quarter progressed. Widespread adoption of work-from-home or shelter-in-place policies caused many of our customers to reduce or suspend their activities, which adversely affected our revenue in the first quarter. The first quarter was not impacted by supply or manufacturing constraints.

Cash and cash equivalents, short-term investments, and restricted cash as of March 31, 2020, totaled approximately \$49.6 million, compared to \$60.7 million at the end of 2019. Cash flows in the quarter included \$5.2 million of cash consideration paid for the acquisition of InstruNor AS and \$3.5 million of cash received pursuant to a licensing and legal settlement.

### 2020 Guidance

Due to the unknown duration and extent of the novel coronavirus's impact on revenue and the uncertainty about how this pandemic will affect our global operations, Fluidigm is withdrawing its 2020 guidance that was provided on February 10, 2020. We expect to update our outlook at such time as the effects of the virus on our business become clearer.

We plan on releasing our full financial and operating results for the first quarter of 2020 and additional information on the impact of the COVID-19 pandemic in our upcoming earnings call, which is expected to be in early May 2020.

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected results for our first quarter ended March 31, 2020. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to differences between our estimated and actual financial results for the quarter ended March 31, 2020, as we finalize our quarter end financial closing procedures; the suitability and acceptance of our tools and technology by the research community pursuing solutions for the novel coronavirus pandemic; our ability and/or the ability of the research institutions

utilizing our products and technology to obtain FDA and any other requisite approvals to use our products and technology for diagnostic testing purposes; customers and prospective customers continuing to curtail or suspend activities utilizing our products; interruptions or delays in the supply of components or materials for, or manufacturing of, our products resulting from the pandemic or other factors; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to reliance on sales of capital equipment for a significant proportion of revenues in each quarter; potential product performance and quality issues; the possible loss of key employees, customers, or suppliers; intellectual property risks; competition; uncertainties in contractual relationships; risks relating to company research and development, sales, marketing, and distribution plans and capabilities; reductions in research and development spending or changes in budget priorities by customers; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm's business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

### **About Fluidigm**

Fluidigm (Nasdaq: FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF<sup>®</sup> and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit [fluidigm.com](http://fluidigm.com).

Fluidigm, the Fluidigm logo, CyTOF, Direct, Immune Profiling Assay, and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

### **Available Information**

We use our website ([fluidigm.com](http://fluidigm.com)), investor site ([investors.fluidigm.com](http://investors.fluidigm.com)), corporate Twitter account (@fluidigm), Facebook page ([facebook.com/Fluidigm](https://facebook.com/Fluidigm)), and LinkedIn page ([linkedin.com/company/fluidigm-corporation](https://linkedin.com/company/fluidigm-corporation)) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

1 Leng, Z., Zhu, R., Hou, W. et al. "Transplantation of ACE2<sup>-</sup> mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia." *Aging and Disease* 11 (2020): 216–228.

### **Contacts:**

#### **Investors:**

Agnes Lee  
Vice President, Investor Relations  
Fluidigm Corporation  
650 416 7423  
[agnes.lee@fluidigm.com](mailto:agnes.lee@fluidigm.com)

#### **Media:**

Mark Spearman  
Senior Director, Corporate Communications  
650 243 6621  
[mark.spearman@fluidigm.com](mailto:mark.spearman@fluidigm.com)